程序性死亡配体1（PD-L1）表达作为晚期非小细胞肺癌的预测生物标志物：更新的生存数据
PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.
作者信息
Aguiar Pedro N, De Mello Ramon Andrade, Hall Peter, Tadokoro Hakaru, Lima Lopes Gilberto de
机构信息
Division of Medical Oncology, Federal University of São Paulo, São Paulo, SP, Brazil.
Department of Biomedical Sciences & Medicine, Division of Oncology, University of Algarve, Faro, Portugal.
出版信息
Immunotherapy. 2017 May;9(6):499-506. doi: 10.2217/imt-2016-0150.
AIM
The treatment of non-small-cell lung cancer has changed after the development of the immune checkpoint inhibitors. Although the most studied biomarker is PD-L1 expression, its clinical significance is still debatable. In this article, we show the updated survival analysis of all published data.
METHODS
We searched in network and conference data sources for relevant clinical studies of immunotherapy for non-small-cell lung cancer that assessed the PD-L1 expression even as an exploratory analysis. The updated survival hazard ratios (HR) were included in the analysis.
RESULTS
14 studies with 2857 patients were included (2019 treated with immunotherapy). The response rate was as higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89).
CONCLUSION
PD-L1 overexpression predicts activity as well as better survival for patients treated with immune checkpoint inhibitors.
目的
免疫检查点抑制剂出现后，非小细胞肺癌的治疗发生了变化。尽管研究最多的生物标志物是PD-L1表达，但其临床意义仍存在争议。在本文中，我们展示了所有已发表数据的最新生存分析。
方法
我们在网络和会议数据源中搜索了评估PD-L1表达（即使作为探索性分析）的非小细胞肺癌免疫治疗相关临床研究。分析纳入了更新后的生存风险比（HR）。
结果
纳入了14项研究，共2857例患者（2019例接受免疫治疗）。PD-L1阳性患者的缓解率更高（RR：2.19，95%CI：1.63-2.94）。PD-L1表达还与更好的无进展生存期（HR：0.69，95%CI：0.57-0.85）和更好的总生存期（HR：0.77，95%CI：0.67-0.89）相关。
结论
PD-L1过表达预示着接受免疫检查点抑制剂治疗的患者有更好的活性和生存期。
Zotero 插件